论文部分内容阅读
目的探讨乌司他丁联合地塞米松治疗伴发MODS的重症急性胆管炎的临床疗效。方法52例伴发MODS的重症急性胆管炎患者随机分为实验组(n=28)和对照组(n=24),实验组使用乌司他丁10万U、地塞米松5mg、奥美拉唑40mg静脉滴注,2次/d;对照组使用地塞米松5mg、奥美拉唑40mg静脉滴注,2次/d。分别监测患者术后多项临床指标,对比2组疗效。结果实验组和对照组治疗后5d功能不全器官恢复率(71.6%vs44.8%)、消化道出血发生率(3.57%vs12.5%)和平均住院时间〔(28.8±2.7)vs(40.6±4.2)d〕,差异均有统计学意义(P<0.01或P<0.05);但2组间治愈率和病死率差异无统计学意义((P>0.05)。结论马司他丁联合地塞米松及奥美拉唑对伴发MODS的重症急性胆管炎有明确的疗效,能加快功能不全器官的恢复,减少消化道出血发生率,并能明显缩短住院时间。
Objective To investigate the clinical efficacy of ulinastatin combined with dexamethasone in the treatment of severe acute cholangitis with MODS. Methods Fifty-two patients with severe acute cholangitis complicated with MODS were randomly divided into experimental group (n = 28) and control group (n = 24). The experimental group received ulinastatin 100 000 U, dexamethasone 5 mg, Azole 40mg intravenous infusion, 2 times / d; control group using dexamethasone 5mg, omeprazole 40mg intravenous infusion, 2 times / d. Patients were monitored after a number of clinical indicators, the efficacy of two groups were compared. Results In the experimental group and the control group, the recovery rate of functional insufficiency (71.6% vs 44.8%), incidence of gastrointestinal bleeding (3.57% vs 12.5%) and average length of stay [(28.8 ± 2.7) vs (40.6 ± 4.2) d], the difference was statistically significant (P <0.01 or P <0.05), but there was no significant difference between the two groups in cure rate and mortality (P> 0.05) Mesangong and omeprazole with severe acute cholangitis associated with MODS have a clear effect, can accelerate the recovery of insufficiency organs, reduce the incidence of gastrointestinal bleeding, and can significantly reduce the length of stay.